EUCTR2014-003401-15-Outside-EU/EEA进行中（未招募）不适用
A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children age 2 years through 6 years
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Healthy by medical history and physical examination OR presence of stable underlying chronic medical condition for which hospitalization has not been required in the previous year. 2. Age 2 through 6 years of age at the time of administration. 3. A written informed consent should be obtained from the subject’s legally acceptable representative. 4. Ability of the parent/guardian to understand and comply with the requirements of the protocol. 5. Parent/guardian available by telephone or email.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 100
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous administration in the present study 2. Participation in another clinical study with an investigational product during the last 3 month 3. Acute illness or evidence of significant active infection at time of investigational product administration 4. Fever =99.5°F (37.5°C) at time of investigational product administration 5. Any drug therapy from 15 days prior to randomization or expected drug therapy through 28 days post last dose with the exception of the following classes/types of medications, which are allowed: Topical corticosteroids, calcineurin inhibitors, or antifungals for uncomplicated dermatitis; Chronic medications (including those taken on an as-needed basis) that have been well tolerated and were not initiated and/or did not have a dosage change within 90 days prior to randomization. 6. Current or expected receipt of immunosuppressive medications within a 28-day window around any dose, including an immunosuppressive dose of corticosteroids, which is defined as =20 mg/day of prednisone or its equivalent, given daily or on alternate days for =15 days (intranasal, intra-articular, and topical corticosteroids are permitted); Note: topical corticosteroids for uncomplicated dermatitis may be used throughout the study according to the judgment of the investigator; topical calcineurin inhibitors may be used in accordance with their package insert at entry and during study participation. 7. Any known immunosuppressive condition or immune deficiency disease including known or suspected infection with human immunodeficiency virus (HIV); 8. History of allergic disease or reactions likely to be exacerbated by any component of the investigational product including allergy to eggs, egg proteins, gentamicin, or gelatin or serious, life threatening, or severe reactions to previous influenza vaccinations; 9. Use of aspirin or salicylate-containing medications within 28 days prior to enrolment or expected receipt through 28 days after final vaccination; 10. History of Guillain-Barré syndrome; 11. Use of antiviral agents with activity against influenza virus (including amantadine, rimantadine, oseltamivir, and zanamivir) within 28 days prior to first dose of investigational product or anticipated use of such agents within 28 days after last scheduled vaccination; 12. Administration of any live virus vaccine within 30 days prior to enrolment, or if receipt of another live virus vaccine is expected within 30 days of any study vaccination; 13. Administration of any inactivated vaccine within 14 days prior to enrolment or if receipt of another inactivated vaccine is expected within 14 days of any study vaccination; 14. Receipt of any blood product within 90 days prior to vaccination or expected receipt during this study; 15. Involvement in the planning and conduct of the study (applies to all AstraZeneca staff and staff at the study site as a parent/guardian) 16. Any condition that, in the opinion of the investigator, might interfere with the interpretation or evaluation of the vaccines.
研究者
相似试验
进行中（未招募）
不适用
An Open Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population - Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine.To verify the safety and immunogenicity of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2009/2010 season, manufactured according to the standard manufacturing process using a fixed Trition-X concentration during the splitting process (Formula A) (Cohort 1) and a modified manufacturing process control using a fixed protein to Triton X-100 ratio during the splitting process of the H3N2 and the B strain (Formulation B) (Cohort 2)MedDRA version: 12.1Level: LLTClassification code 10022000Term: InfluenzaEUCTR2009-017781-23-BEBaxter Innovations GmbH220
进行中（未招募）
不适用
An Open Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population - ADULT SAFETY STUDY OF 2009/2010 SEASONAL INFLUENZA VACCINE.EUCTR2009-017781-23-ATBaxter Innovations GmbH220
进行中（未招募）
1 期
Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis SubjectsCystic FibrosisEUCTR2019-003455-11-DEVertex Pharmaceuticals Incorporated158
进行中（未招募）
1 期
Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis SubjectsMedDRA version: 20.0 Level: PT Classification code 10011762 Term: Cystic fibrosis System Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2019-003455-11-GBVertex Pharmaceuticals Incorporated158
进行中（未招募）
1 期
A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects With Cystic FibrosisMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2020-004885-21-BEVertex Pharmaceuticals Incorporated143